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Abstract
Mitochondrial diseases are a prevalent, heterogeneous class of diseases caused by
defects in oxidative phosphorylation, whose severity depends upon particular genetic
mutations. These diseases can be difficult to diagnose, and current therapeutics have
limited efficacy, primarily treating only symptoms. Because mitochondria play a pivotal
role in numerous cellular functions, especially ATP production, their diminished activity
has dramatic physiological consequences. While this in and of itself makes treating
mitochondrial disease complex, these organelles contain their own DNA, mtDNA,
whose products are required for ATP production, in addition to the hundreds of
nucleus-encoded proteins. Drosophila offers a tractable whole-animal model to understand the mechanisms underlying loss of mitochondrial function, the subsequent cellular and tissue damage that results, and how these organelles are inherited. Human and
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Drosophila mtDNAs encode the same set of products, and the homologous nucleusencoded genes required for mitochondrial function are conserved. In addition, Drosophila contain sufficiently complex organ systems to effectively recapitulate many
basic symptoms of mitochondrial diseases, yet are relatively easy and fast to genetically
manipulate. There are several Drosophila models for specific mitochondrial diseases,
which have been recently reviewed (Foriel, Willems, Smeitink, Schenck, & Beyrath,
2015). In this review, we highlight the conservation between human and Drosophila
mtDNA, the present and future techniques for creating mtDNA mutations for further
study, and how Drosophila has contributed to our current understanding of mitochondrial inheritance.

1. MITOCHONDRIA PLAY DIVERSE ROLES
Mitochondria are thought to have arisen through endosymbiosis
(Margulis, 1970). As such, in metazoans mitochondria are the only organelle, other than the nucleus, which contains its own DNA, mtDNA. The
mtDNA in different species encodes a variable number of products; however, animal mtDNA represents the most stripped-down version of the
genome (Gray, 2012). The 16 kb human mtDNA codes for 13 proteins,
22 tRNAs, and 2 rRNAs. All 13 proteins are components of the electron
chain complexes (ETC) I, III, IV, and V (the ATP synthase). Almost all
the DNA is coding—for example, there are no introns in the resulting
mRNAs and very few gaps in coding sequence. Drosophila mtDNA encodes
the same transcripts as human mtDNA, albeit in a slightly different genomic
order (Fig. 1). This fundamental similarity makes the fly an excellent model
for studying mitochondrial function.
The evolution between the nucleus and mitochondria has culminated in
mitochondria taking on highly specialized functions, offering an environment
to support a variety of biochemical reactions required for the cell. Because
mitochondria have such a small genome, they rely heavily on imported
proteins encoded in the nucleus. The best known mitochondrial product is
ATP, produced via the ETC and oxidative phosphorylation (OXPHOS).
However, mitochondria are also required for fatty acid beta oxidation, heme,
steroid, and nucleotide biosynthesis and are integral to apoptosis. In fact, under
specialized conditions it is possible for yeast and cultured cells to survive
without functional OXPHOS (i.e., loss of mtDNA); however, they cannot
survive in the complete absence of the organelle (Chandel & Schumacker,
1999; Goldring, Grossman, Krupnick, Cryer, & Marmur, 1970; Morais,
Gregoire, Jeannotte, & Gravel, 1980; Nagley & Linnane, 1970). All of these
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Fig. 1 Human and Drosophila mitochondrial DNA encode the same products. Human mtDNA (top) is approximately 3 kb shorter than
Drosophila mtDNA (bottom). The size difference is predominantly due to the expanded “A + T-rich” region in Drosophila, which varies among
different Drosophila species. Human mtDNA is transcribed as three polycistrons (arrows): two for the heavy strand (HS), which encodes most
of the products, and one for the light strand (LS). The LS promoter (LSP) starts in the D-loop region (indicated by dashed line), where the origin
of replication is found. HSP1, which includes the rRNAs, expresses at higher levels compared to HSP2. Drosophila mtDNA is thought to be
transcribed as five polycistrons. Note that the products are relatively evenly encoded on both strands, in contrast to human mtDNA. Some
segments maintain the same sequence (e.g., ATP8 ! mt:tRNAGly). ATP, ATP synthase (orange, Complex V); CO, cytochrome c oxidase
(purple, Complex IV); Cytb, cytochrome b (yellow, Complex III); ND, NADH dehydrogenase (green, Complex I).
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basic biochemical reactions are required for both Drosophila and human
cells, and because Drosophila mtDNA encodes the same products as human
mtDNA, Drosophila mitochondria function requires essentially the same
nuclear genes as human mitochondria.

2. MITOCHONDRIAL DISEASES—CAUSES AND EFFECTS
Human mitochondrial diseases mostly result from a loss of OXPHOS.
The term “mitochondrial function” is used broadly so it is important to be as
specific as possible when characterizing any particular loss in biochemical
function. There are estimated to be between 1000 and 1500 proteins
encoded in the nucleus that are imported or associated with mitochondria
(Area-Gomez & Schon, 2014). Thus, mitochondrial disease arises through
mutations in either nuclear DNA or mtDNA. As with any nuclear gene,
mitochondrial disease due to mutations in nuclear genes can be inherited
in a Mendelian fashion as either a dominant or recessive trait. In comparison
to mutations in disease-causing nucleus-encoded mitochondrial genes, there
are over 250 verified disease-causing point mutations in mtDNA. Because
mitochondria cannot be made de novo, they are inherited through the
mother, and thus mtDNA mutations are exclusively maternally inherited.
The 13 proteins encoded by mtDNA are translated in the mitochondrial
matrix using mtDNA-encoded tRNAs (mt:tRNAs) and the mitochondrial
ribosome, which consists of the mt:rRNAs and nucleus-encoded proteins.
This suite of mt:tRNAs is all that is required for translation in human and
Drosophila mitochondria. Human and Drosophila mtDNA is transcribed as
a series of polycistrons (Fig. 1). The mt:tRNAs are thought to function as
“punctuation,” with most of the mRNAs separated by at least one mt:tRNA
(Ojala, Montoya, & Attardi, 1981). Thus, it is critical that each mt:tRNA
and every product of the genome be properly excised allowing each mRNA
to be further processed and translated. Of the known disease-causing point
mutations in mtDNA, over half are found in mt:tRNAs. This is somewhat
surprising, given that the 22 mt:tRNAs encode only 9% of the genome. One
explanation could be that mutations in the protein-coding regions are too
deleterious and incompatible with life.
The known mutations that cause human mitochondrial disease have
been extensively reviewed (Area-Gomez & Schon, 2014; Chinnery,
1993; Dimauro & Davidzon, 2005; Lightowlers, Taylor, & Turnbull,
2015). In general, they give rise to defects in the musculature and nervous
system. However, while mutations in nuclear DNA and mtDNA would be
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expected to cause a decrease in OXPHOS, the different mutations have variable onset and features, from symptoms as mild as eye muscle weakness
(external ophthalmoplegia) to infant mortality. There is even evidence that
defects in OXPHOS may be a cause of miscarriage (Tay, Shanske, Kaplan, &
DiMauro, 2004). Why deficits in the proteins involved in ATP production
give rise to such different outcomes largely remains a mystery. In the case of
disease caused by mutations in nuclear genes, all cells should have the same
genotype. However, for mutations in mtDNA, one reason for differences in
tissue deficits could be the threshold effect (Picard et al., 2014; Rossignol
et al., 2003; Stewart & Chinnery, 2015). Each cell contains many mitochondria, and each mitochondrion usually contains multiple copies of mtDNAs.
Mutations in mtDNAs are usually heteroplasmic (a mixture of wild type and
mutant), thus tissues with a higher mutation load would be expected to be
more severely affected. But a recent finding suggests that many associated
symptoms, secondary to a prominent trademark phenotype that arose
beyond the threshold point, can appear even when a particular mutation
load is well below the threshold mark. Picard and colleagues found that a
predominant pathogenic mutation in a mitochondrial tRNA gene (mtDNA
3243A > G; mutation in mt:tRNALeu(UUR)) has an effect on nuclear gene
expression when present at well below the threshold point (Picard et al.,
2014). Heteroplasmic cells harboring different mutational loads of this particular mutation have striking variations in their gene expression profile.
This could explain why patients with the same mutation manifest different
clinical symptoms. For example, patients with mtDNA 3243A > G that have
high levels of mutated mtDNA exhibit mitochondrial encephalomyopathy,
whereas patients with lower levels can suffer from type II diabetes, deafness,
or even be on the autistic spectrum (Goto, Nonaka, & Horai, 1990; Pons
et al., 2004; van den Ouweland et al., 1992).

3. HOW CAN STUDYING DROSOPHILA CONTRIBUTE TO
OUR UNDERSTANDING OF HUMAN MITOCHONDRIAL
DISEASES?
As a model organism, Drosophila can help our understanding of mitochondrial diseases in several specific ways. The first takes advantage of the
rich history of cell biology in Drosophila. From dissected tissues taken from
wild-type and mutant flies, mitochondria can be clearly visualized at the
organelle level in fixed or live tissues (Cox & Spradling, 2006; Sen,
Damm, & Cox, 2013). This allows for a detailed and accurate view of
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location, numbers, and morphology. In addition, with molecular and biochemical assays, researchers can assay which mitochondrial functions are
compromised in vivo in Drosophila carrying various gene mutations.
The second advantage to using Drosophila to study deficits in mitochondrial function is that they have complex central and peripheral nervous systems, and contain the various organ systems that are frequently affected in
humans suffering from mitochondrial disease, such as skeletal and heart muscles. These organ systems are far simpler than those in humans, allowing for
detailed analysis of the progression of tissue degeneration either during
development or aging. Seizures are one feature of mitochondrial diseases
such as myoclonic epilepsy with ragged-red fibers (MERRF) and mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes
(MELAS). This clinical feature is easily mimicked in Drosophila by assaying
for bang-sensitivity, the paralysis and seizures that can occur after mechanical
stimulation (Engel & Wu, 1994; Fergestad, Bostwick, & Ganetzky, 2006;
Ganetzky & Wu, 1982). Bang-sensitivity occurs in mutants for several genes
involved in metabolism in general, and mitochondrial function in particular
(Burman et al., 2014; Celotto et al., 2006; Fergestad et al., 2006; Royden,
Pirrotta, & Jan, 1987; Zhang et al., 1999). Another symptom of certain
mitochondrial diseases is brain degeneration which can cause cerebellar
ataxia, for example, found in MELAS, Leigh syndrome and myoclonic epilepsy, myopathy, and sensory ataxia. Drosophila with mtDNA mutations
with bang-sensitivity also exhibit progressive brain degeneration (Burman
et al., 2014; Celotto et al., 2006). Finally, cardiomyopathy occurs with
mutations of multiple nucleus-encoded and mtDNA-encoded genes
(Antonicka et al., 2003; Jaksch et al., 2000; Loeffen et al., 2001;
Majamaa-Voltti, Peuhkurinen, Kortelainen, Hassinen, & Majamaa, 2002;
Papadopoulou et al., 1999; Wahbi et al., 2010). In Drosophila, knockdown
of several proteins found in the ETC Complex I (NDUFS2, NDUFS7, and
NDUFC2) specifically in the heart caused significant, abnormal heart dilation (Tricoire, Palandri, Bourdais, Camadro, & Monnier, 2014).
An additional advantage is the ease of genetic manipulation in Drosophila.
RNAi knockdown of single proteins in each ETC complex can be temporally and spatially controlled using the UAS/GAL4 system, which has been
done for a subset of ETC and OXPHOS proteins (listed in table 1 of
Foriel et al., 2015). In addition, mutant analysis has been very helpful in
determining the molecular mechanisms underlying mitochondrial dysfunction, sometimes offering unexpected results. For instance, tko25t (technical
knockout) is a recessive mutation in the nucleus-encoded mitochondrial
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ribosomal protein S12. This bang-sensitive mutation confers a developmental
delay and has long been considered a model for mitochondrial disease because
the mutation targets the respiratory chain and causes seizures and deafness
(Jacobs et al., 2004; Toivonen et al., 2001). The main pathological symptom
identified in tko25t was oxidative stress. Thus, it was assumed that decreasing
oxidative stress would ameliorate the effect of the tko mutation. However, a
recent finding shows that expressing neither the alternative oxidase (AOX,
from Ciona instestinalis) nor NADH dehydrogenase (ndi1, from yeast) could
rescue the phenotype of tko25t mutant flies (Kemppainen, Kemppainen, &
Jacobs, 2014). These results imply that the tko25t mutation affects greater mitochondrial function such that merely targeting oxidative stress cannot afford a
remedy.
A major challenge in mitochondrial disease therapy is establishing the
root cause against which potential therapeutics can be generated. While
the pathological manifestation of a mitochondrial disease looks simple,
namely, loss of OXPHOS, it is difficult to dissect what component(s) of that
complex structure is compromised. The basic functional moiety of a mitochondrion is its OXPHOS network. For example, if one of the 44 components of Complex I does not function properly, it may be reflected in
abnormal Complex I activity. However, a traditional clinical approach
may not be adequate to identify the primary cause of the nonfunctional
Complex I, whereas a model system allows various forms of experimentation not possible in patients. Even if a particular subunit is mutated, it can be
difficult to predict what specific aspect of the molecular complex is deficient.
This creates difficulties for rational therapeutic design. Thus, using Drosophila offers tremendous potential for identifying the exact molecular mechanism behind any pathological symptoms and could aid in more targeted
drug delivery and discovery.

4. MITOCHONDRIAL DISEASES CAUSED BY mtDNA
MUTATIONS
Since mitochondria cannot be made de novo and contain their own
DNA, they are maternally inherited through the egg’s cytoplasm. Thus,
mutations in mtDNA, and therefore mitochondrial diseases, are inherited
through the mother. Common mitochondrial diseases occur from point
mutations in all products encoded by mtDNA: protein-coding regions,
tRNAs, and rRNAs. For example, maternally inherited forms of Leber
hereditary optic neuropathy are due to point mutations in the subunits of
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the NADH dehydrogenase complex (Complex I) ND1, ND2, ND4, and
ND4L. Point mutations in different mt:tRNAs cause different symptoms
and disease (MELAS, MERRF, CPEO as a few of the examples). All of these
mutations have effects on the stoichiometry of the protein complexes used
for OXPHOS which is the underlying cause of a decrease in mitochondrial
output.
What have we learned from flies harboring deleterious mutation in their
mtDNA? Currently, there are three fly models to examine specific mutations; however, this is an area with great potential (discussed later). The first
model is a serendipitously identified point mutation in mt:ATP6 (Celotto
et al., 2006). The bang-sensitivity of Drosophila mutant for adenine nucleotide translocase type 1 (ANT1, called stress sensitive (SesB) in Drosophila) was
separable from a second, cytoplasmically inherited bang-sensitivity found to
be caused by a single point mutation in mt:ATP61. The mt:ATP61 mutation
exists at near homoplasmy and gives rise to neurodegenerative phenotypes
reminiscent of those found in mitochondrial diseases caused by mutations in
ATP6. This model has been useful for studying the bioenergetic changes
that occur before and after neurological symptoms occur (Celotto, Chiu,
Van Voorhies, & Palladino, 2011).
The second model used a mitochondrially targeted restriction endonuclease to generate a single-site cleavage in the mtDNA. This idea was first
tested in tissue culture cells by the Moraes laboratory, then subsequently successfully used in Drosophila to create an intact organism containing a mutation in cytochrome c oxidase subunit I (mt:CoI, Complex IV) as well as a
small insertion and small deletion in mt:ND2 (mt:ND2ins1 and mt:ND2del1,
respectively) (Bacman, Williams, Pinto, & Moraes, 2014; Srivastava &
Moraes, 2001; Xu, DeLuca, & O’Farrell, 2008). In Drosophila, a single XhoI
site is located in CoI. Xu et al. conditionally expressed a transgene encoding
mitochondrially targeted XhoI exclusively in the germline. Upon germline
expression, most mtDNA was irreparably cleaved, giving rise to sterile
females; however, at a low level, mtDNA with mutations which rendered
the DNA impervious to XhoI cleavage were selected for. These mutations
were able to replicate and repopulate the germline. As would be expected,
certain mutations were silent; however, others caused amino acid changes
that affected CoI function (Xu et al., 2008). Adults homoplasmic for mt:
CoIR301S mtDNA had 50% of the normal CoI levels, age-related reduction
in ATP levels, and neurological and muscular defects, thus largely recapitulating many of the general symptoms exhibited in human mitochondrial
diseases.
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The mt:ND2del1mutation, which removes three highly conserved residues at positions 186–188, was recently further characterized (Burman
et al., 2014). This work is a good example of how Drosophila exhibit tissue
phenotypes associated with human mitochondrial disease, while also helping
define the molecular function of a particular protein in one of the ETC
Complexes. Complex I is the largest complex, with 44 proteins. Burman
et al. found that mt:ND2del1 mutants were bang-sensitive and had reduced
life spans, similar to mt:ATP61 mutants. The mutant adults had neurodegenerative vacuoles in aged fly brains, suggesting a progressive neurodegenerative phenotype, while the musculature remained intact. To pinpoint any
defects in respiration, the authors determined that under maximally
demanding conditions, the mutants showed a Complex-I-dependent respiratory defect, but no defect in Complex-II- and Complex-IV-dependent
respiration. The total amount of assembled CoI was reduced, as was the
mitochondrial membrane potential and amount of ATP. Together, these
data support a role for mt:ND2 in the proton pumping mechanism of Complex I, the first time this has been shown in a eukaryote.
There are also disadvantages to using Drosophila to study mtDNA mutations. One disadvantage is that any organism with a high mtDNA mutational
load will potentially eventually die. Therefore, while it is trivial to maintain a
lethal mutation in a nuclear gene in Drosophila, maintaining mtDNA mutations can be challenging over many generations. In the case of the mt:ATP61
mutation, for reasons that are unknown, this mutation is sustained nearly
homoplasmically in a background of the SesB1 allele of ANT1. Thus, to
examine and characterize the effect of a 100% mt:ATP61 mutation load,
the SesB mutation need simply be crossed out of the strain. In the case of
the CoI mutation located at the XhoI restriction site, while this stock will
eventually die, it can be generated reproducibly over and over again by
expressing the mitochondrially targeted XhoI in the germline.

5. DISEASE-CAUSING POINT MUTATIONS ARE MOST
PREVALENT IN mt:tRNAs—CONSERVATION BETWEEN
HUMAN AND DROSOPHILA
A thorough and continuously updated compilation of human mtDNA
mutations and polymorphisms indicates that there are a total of 305 diseasecausing modifications in mt:tRNAs and mt:rRNAs, with the numbers likely
growing (Lehmann et al., 2015; Lott et al., 2013). This is an unusually large
number given that only about 9% of mtDNA codes for tRNAs. There are
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various nucleus-encoded factors that are involved in processing mt:tRNA
from their immature transcripts, as well as those that are responsible for posttranslational modifications. Mutations in mt:tRNA residues that are sites for
processing and modification can cause mitochondrial disease (Powell,
Nicholls, & Minczuk, 2015). What are the possible effects of these mutations? mt:tRNA mutations may affect tRNA processing. Mature mt:tRNAs
are embedded within the newly synthesized polycistronic transcript (Fig. 1).
Due to this “punctuation” model, precursor mt:tRNA processing is critical
not only to generate mature mt:tRNAs but also to cleave out the mt:
mRNAs (Ojala et al., 1981). Recently, the mitochondrial cognate of RNase
Z, the endoribonuclease responsible for 30 -end tRNA cleavage, was identified in Drosophila. The authors showed that specific loss of the mitochondrial form affected mt:RNA processing, causing larval lethality, cell-cycle
defects, and an increase in reactive oxygen species (Xie & Dubrovsky,
2015). A mitochondrial protein-only RNase P, containing no enzymatic
RNA, performs the 50 -end cleavage of mt:tRNAs (Holzmann et al.,
2008). Recently, the three Drosophila orthologs comprising this complex
have been identified and abolishing any of them causes lethality, loss of
ATP, and aberrant mt:RNA processing (Sen et al., 2016). Potentially, mutations in the nucleotide residues that participate in the interaction between
the mt:tRNA and either of these enzyme complexes responsible for cleavage
could hinder processing, leading to not only a reduction in mt:tRNAs but
also normal polycistron processing.
A second possible effect of mt:tRNA point mutations is on their unique
stem–loop hairpin structure since the primary sequence is responsible for
forming this secondary conformation. Mutations in residues contributing
to this stable structure may lead to unstable mt:tRNA molecules that could
be susceptible to enzymatic degradation. For example, a recent study by Duff
et al. described how a single mutation in mt:tRNATrp caused a wide range of
defects (Duff et al., 2015). A homoplasmic 5559A > G mutation in cells from
a family affected with Leigh syndrome not only altered the processing and
stability of mt:tRNATrp but also affected the stability of many other mitochondrial tRNAs, mRNAs, and rRNA.
Another tRNA-specific problem could be due to improper charging.
The main function of tRNAs is to read the genetic code and transfer the
respective amino acid residues onto the nascent polypeptide. But to do
so, tRNAs must get charged with the appropriate amino acid by aminoacyl
tRNA synthetase (ARS). In mitochondria, this charging process requires
cross talk between nucleus-encoded mitochondrial tRNA synthetase
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(mtARS) and mt:tRNAs (Tyynismaa & Schon, 2014). As these two components rely on each other for proper function, mutations in either may lead
to a cascade of functional abnormalities. For example, mutations in 9 of
19 total mtARs, encoded by the nuclear genome, are associated with mitochondrial disease in a tissue-specific manner (Konovalova & Tyynismaa,
2013). Despite having wide-spread consequences in causing mitochondrial
disease, mutations in mt:tRNAs are not yet treatable. Repairing these mutations is not possible, due to the maternal inheritance of mtDNA. Recent
studies have shown that their functional incompatibility can lead to developmental defects in Drosophila, and cell growth defects in yeast and mammalian cell culture (Meiklejohn et al., 2013; Perli et al., 2016; Wang et al.,
2016). However, researchers have shown that engineered nucleus-encoded
mtARSs can be used to suppress the effect of deleterious mt:tRNA mutations, which is easier to accomplish than altering mtDNA.
A comprehensive list of diseases related to mutations in mt:tRNAs is
available at Mitomap (Brandon et al., 2005; Ruiz-Pesini et al., 2007).
Due to their prevalence, there is a great deal of interest in mt:tRNAs point
mutations and how they contribute to disease (Yarham, Elson, Blakely,
McFarland, & Taylor, 2010). Using Drosophila to model human mitochondrial diseases caused by mt:tRNA mutations would be useful to determine
the specific effect each mutation has on mt:tRNA processing, stability, and/
or modification. To highlight the conservation between Drosophila and
human mt:tRNAs, Fig. 2 shows a pair-wise structural alignment of all
22 tRNAs using the LocARNA alignment tool (Smith et al., 2010; Will,
Joshi, Hofacker, Stadler, & Backofen, 2012). This program compares primary sequences as well as the structural compatibility of input RNA
sequences, which is especially important as this indicates any potential disruptions caused by different mutations on secondary structure. Using
LocARNA, all mt:tRNA pairs produce highly compatible canonical cloverleaf tRNA structures (examples shown in Fig. 2C and D), except for mt:
tRNASer(AGY) and mt:tRNAPro. The confirmed disease-causing point
mutations are marked with asterisks below each pair. We have also marked
the residues where unique mutations have been reported (Genebank frequency 0, thus not due to polymorphism). Of a total of 145 mutant residues,
77 are conserved in Drosophila, and some of these conserved residues, which
are structurally more compatible than others, would be excellent targets for
mutagenesis. Using these alignments, along with weighted-based pathogenicity scoring models, allows prioritization of which residues would be best
targeted for mutation studies (Blakely et al., 2013; Yarham et al., 2011).
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.........10........20........30........40........50..................

**

A
GA
CA
UA
AU
AU
GA
U _
_
_ _ A
U AU CUCAU
_
U
G
A C
G
G
G
U
_
AAA
ACG
C
_
CGC
A
_
G
G
A
UA A
A A_A
C3256T A A
G3255A
AU
A3260G A C
mt:tRNA Leu
AC
C
A
U
A
UA A

D

* *

*

Glu Hs
Dm

** *

*

(((((((..((((.....)))).(((((.(...).)))))....(((((......)))))))))))).

Hs
Gly Dm

*

9991 ACUCUUUUAGUAUAAAUAGUACCGUUAACUUCCAAUUAACUAGUUUUGACAACAUUCAAAAAAGAGUA 10,058
5543 AUCUAUAUAGUAUAAA-AGUAUAUUUGACUUCCAAUCAUAAGGUCUAUU--AAUUAAUAGUAUAGAUA 5607
.........10........20........30........40........50.................

**

His Hs
Dm

(((((((..((((.....))))((((((((...))))))))...(((((.......)))))))))))).
12,138 GUAAAUAUAGUUUAACCAAAACAUCAGAUUGUGAAUCUGACAACAGAGGCUUACGACCCCUUAUUUACC 12,206
8205 AUUUAAAUAGUUUAAAAAAAAUACUAAUUUGUGGUGUUAGUGAUAUGAA---AAUAUUCAUUUUAAAUC 8140
.........10........20........30........40........50..................

**

Ile Hs
Dm

*

*

*

(((((((..(((.......))).(((((((...))))))).....(((((.......))) ))))))))).

4263 AGAAAUAUGUCUGAU-AAAAGAGUUACUUUGAUAGAGUAAAUAAUAGGAGCUUAAACCCC CUUAUUUCUA 4331
1 AAUGAAUUGCCUGAUAAAAAGGAUUACCUUGAUAGGGUAAAUCAUGCAGUUUU-----CU GCAUUCAUUG 65
.........10........20........30........40........50......... .........7

* ** **

**** **

*

(((((((..(((............))).(((((.......))))).....((((((.....))))))))))))).
UUCCUCUUCUUAACA 3304
Leu Hs 3230 GUUAAGAUGGCAGAGCCCGGUAAUCGCAUAAAACUUAAAACUUUACAGUCAGAGGUUCAA
UCUAAUAUGGCAGA------UUAGUGCAAUAGAUUUAAGCUCUAU-AUAUAAAGUAUU--UUACUUUUAUUAGAA 3077
(UUR)Dm 3012 .........10........20........30........40........50..................70....

***

****** ** *

* *

*

***

**

(((((((..(((((.....))))).((((((....).)))))....(((((.......)))))))))))).

Leu Hs 12,266 ACUUUUAAAGGAUAACAGCUAUCCAUUGGUCUUAGGCCCCAAAAAUUUUGGUGCAACUCCAAAUAAAAGUA 12,336
(CUN) Dm 12,733 ACUAUUUUGGCAGAUUAG---UGCAAUAAAUUUAGAAUUUAUAUAUGUGAUUU---UUAUUACAAAUAGUA 12,669
.........10........20........30........40........50..................70

* * *

** **

(((((((..(((.......)))((((((.......))))))....(((((.........)))))))))))).

Lys Hs
Dm

8295 CACUGUAAAGCU--AACUUAGCAUUAACCUUUUAAGUUAAAGAUUAAGAGAACCAACACCUCUUUACAGUGA 8364
3768 CAUUAGAUGACUGAAAGCAAGUACUGGUCUCUUAAACCAUUUAAUAGUAA-AUUAGCACUUACUUCUAAUGA 3838
.........10........20........30........40........50..................70.

* * ***

*

**

*

***

**

*

(((((((..((((.....))))((((((.......))))))...(((((.......)))))))))))).

A
G8363A
CG
T8362G
AU
CA
UA
A C T8355C
T8306C
GA
C A CA
A AU
A _ _
UCAUC
A
A
A
UCA
A AGA A
C
A
_ A CC
U
C A GC
A
AA A
CA G
UA
AC
AC
CCA
mt:tRNALys
U
A
C
A
UU

E

Met Hs
Dm

4402 AGUAAGGUCAGCUAAAUAAGCUAUCGGGCCCAUACCCCGAAAAUGUUGGUUAU-ACCCUUCCCGUACUA 4469
171 AAAAAGAUAAGCUAAUUAAGCUACUGGGUUCAUACCCCAUUUAUAAAGGUUAUAAUCCUUUUCUUUUUA 239

Hs
Phe Dm

577 GUUUAUGUAGCUUACCUCCUCAAAGCAAUACACUGAAAAUGUUUAGACGGGCUCACAUCACCCCAUAAACA 647
6401 AUCCAAAUAGCUUA--UACU-AGAGUUUGACAUUGAAGAUGUUAUGGAGAUUAU---UAAAUCUUUGGAUA 6337

.........10........20........30........40........50..................

**

**

*

(((((((.(((((.........)))))(((((((...)))))))....((((.......))))))))))).
.........10........20........30........40........50..................70

*** **

* *

* *

*

*

*

Pro Hs
Dm

(((((((.(((((.((((....(((((((((...)))))))))....)))))))...)).))))))).
16,023 CAGAGAAUAGUUUAAAUUAGAAUCUUAGCUUUGGGUGCUAAUGGUGGAGUUAAAGACUUUUUCUCUGA 15,956
9963 AGG----UAGUUU-AUUUAAAAUAUUAAUUUUGGGGAUUAAUG--AAAAAGAAAUUUCUUUUCUCUUG 9903
.........10........20........30........40........50.................

Ser Hs

((((((((.........((((((.(....)))))))......(((((.......))))))))))))).
12,207 GAGAAAGC----UCA--CAAGAACUGCUAACUCAUGCC--CCCAUGUCU-AACAACAUGGCUUUCUCA 12,265
6184 GAAAUAUGAUGAUCAAGUAAAAGCUGCUAACUUUUUUCUUUUAAUGGUUAAAUUCCAUUUAUAUUUCU 6251
.........10........20........30........40........50.................

*

(AGY) Dm

*

*

*

*

** *

*

((((((..((((((...))))))((((((((...))))))))..((((((.......)))))))))))).

Ser Hs 7514 GAAAAA-GUCAUGGAGGCCAUGGGGUUGGCUUGAAACCAGCUUUGGGGGGUUCGAUUCCUUCCUUUUUUG 7446
(UCN) Dm 11,637 AGUUAAUGAGCUUGA-AUAAGCAUAUGUUUUG--AAAACAUAAGAUAGAAUUUAAUUUUCUAU-UAACUU 11,702
.........10........20........30........40........50..................7

**

Hs
Thr Dm

*** *

***

((((((((.((((......)))))(((((.(...).)))))....((((.....)))))))))))..
15,888 GUCCUUGUAGUAUAAACUAAUACACCAGUCUUGUAAACCGGAGAUGAAAACCUUUUUCCAAGGAC-A 15,953
9837 GUUUUAAUAGUUU-AAUAAAAACAUUGGUCUUGUAAAUCAAAAAUAAGAUUAUUUCUUUUAAAACUU 9902
.........10........20........30........40........50................

*

*

*

((((((((.((((.......))))))(((.((....))..)))..((((((....)))))))))))).

Trp Hs
Dm

5512 AGAAAUUUAGGUUAAAUACAGACCAAGAGCCUUCAAAGCCCUCAGUAAGUUGCAAUACUUAAUUUCUG 5579
1264 AAGGCUUUAAGUU-AAUA-AAACUAAUAACCUUCAAAGCUAUAAAUAAAGAAAUUUCUUUAAGCCUUA 1329

Tyr Hs
Dm

5891 GGUAAAAUGGCUGA--GUGAAGCAUUGGACUGUAAAUCUAAAGACAGGGGUUAGGCCUCUUUUUACCA 5826
1468 GAUUAAGUGGCUGAAGUUUAGGCGAUAGAUUGUAAAUCUAUAUAUAAGAUUUA--UUCUUCUUAAUCA 1403

.........10........20........30........40........50.................

***

* ** ** *

*

(((((((..(((((...))).)).(((((((...)))))))....(((((.....)))))))))))).
.........10........20........30........40........50.................

*

Val Hs
Dm

(((((((..((((........)))).(((((.......)))))....(((((.......) )))))))))))..
1602 CAGAGUGUAGCUUAACA--CAAAGCACCCAACUUACACUUAGGAGAUUUCAACUU-AACU UGACCGCUCUGA- 1670
14,130 CAAUUUAAAGCUUAUUAAGUAAAGUAUUUCAUUUACAUUGAAAAGAUUUUUGUGCAAAUC AAUAUAAAUUGAG 14,058
.........10........20........30........40........50......... .........70..

**

*

***

*

Fig. 2 mt:tRNA comparison between human and Drosophila. (A) A graph showing the
amino acid composition (in percent) of mitochondria-encoded proteins in human and
Drosophila. Amino acids are represented in single letter code. The number of diseasecausing point mutations in each mt:tRNA are indicated at the top of each column.
(B) Pair-wise alignment between human and Drosophila mt:tRNAs using the web-based
LocARNA tool. The tRNA sequences were obtained from human (accession # NC_
012920) and Drosophila (accession # U37541) mitochondrial genome sequences. The
nucleotide start of each sequence is on the left. The gray boxes underneath each alignment indicate conserved nucleotide identity. To show the general location of the stems
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Arrows point to conserved disease-causing residues on the consensus structures of mt:tRNALys and mt:tRNALeu (Fig. 2D and E). These two tRNAs,
along with mt:tRNASer, are the most frequently mutated mt:tRNAs in
mitochondrial disease (Lott et al., 2013; Ruiz-Pesini et al., 2007).

6. DROSOPHILA MODELS OF mtDNA-INDUCED DISEASE:
UNTAPPED FUTURE POTENTIAL
There are multiple, devastating maternally inherited mitochondrial
diseases. Developing additional fly models containing mtDNA mutations
would be very useful for understanding the effect of each specific mutation
on assembly and level of ETC complexes, on different tissues, and for
determining how and what level of mutation load gives rise to deficits in
organ and cell-type function. In addition, being able to generate specific
mtDNA mutations at will would allow researchers to determine at the
cellular and developmental level the molecular mechanisms governing
inheritance. Given that there are only three models for mtDNA mutations
in flies (ATP61, mt:CoI, and mt:ND2), what are the future prospects for generating more?
There are several potential ways to generate models of mtDNAdependent mitochondrial disease in Drosophila. The first way is to use the
restriction endonuclease method described earlier to generate mutations
in mtDNA (Xu et al., 2008). This method has the advantage that it appears
robust in manufacturing escaper flies harboring mtDNA mutations through
germline selection. Furthermore, this method can be used repeatedly to
regenerate the fly stock, since the genetics underlying the technique is
relatively simple. However, the disadvantage is that these single-cut endonucleases recognize specific locations in the fly mtDNA genome, which
limits the number of positions that would be affected (Table 1). In addition,
any given location is not guaranteed to have a deleterious effect.
and loops, a schematic of a canonical tRNA cloverleaf structure in stretched-form is
shown at the top, with the complementary stems the same color. (C) The color
coding indicates whether the nucleotides are conserved and if they form a Watson–
Crick base pair. The color-coding matrix for sequence compatibility was obtained
from the LocARNA site (Smith, Heyne, Richter, Will, & Backofen, 2010). (D and E)
mt:tRNALeu(UUR) (D) and mt:tRNALys (E) show generalized compatible secondary structures for each tRNA based on the sequence alignment. The arrows indicate some
common point mutations found in human mitochondrial diseases that are conserved
in Drosophila.
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Table 1 Restriction Endonucleases with Only One Site in Drosophila melanogaster
Mitochondrial DNA
Endonuclease
Site
Gene

BsmFI

287

ND2

BsrBI

558

ND2

BglII

800

ND2

EcoRV

1359

tRNACys

NruI

1473

COI?

BsgI

1642

COI

Bst1107I

2005

COI

Tsp45I

2182

COI

AvaI

2368

COI

XhoI

2368

COI

NsiI00

3158

tRNALeu

SapI

3310

COII

NciI

3646

COII

DrdI

4245

ATPase 6

BssSI

4922

COIII

StyI

4938

COIII

PleI

5305

COIII

AhdI

5462

COIII

HpaI

6751

ND5

AflII

7417

ND5

PstI

7514

ND5

Bsu36I

9613

ND4L

BsaBI

10,671

CytB

BsmBI

10,711

CytB

NdeI

11,656

tRNASer

BbsI

13,160

lrRNA

BsrGI

14,207

srRNA

BanI

14,741

srRNA

8 out of the 13 protein-coding regions have sites and only 3 out of 22 mt:tRNAs have sites.
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To get around this problem, a method that is beginning to be explored
involves the evolving technology of genome editing combined with
mitochondrially targeted nucleases. Transcription activator-like effector
nucleases (TALEN) technology has recently been shown to abolish neurogenic weakness with ataxia and retinitis pigmentosa-associated mtDNA
mutations in patient heteroplasmic cells by targeting and cleaving mutated
mtDNAs (Reddy et al., 2015). TALEN technology targeting nuclear genes
has been shown to be robust in Drosophila, thus adapting the modification of
mitochondrially targeted TALEN developed for mammals could be used to
cleave the Drosophila mtDNA genome at any site (Beumer et al., 2013;
Katsuyama et al., 2013; Liu et al., 2012; Zhang, Ferreira, & Schnorrer,
2014). This method could potentially generate escaper flies repopulated
with nuclease-resistant mtDNA, as is the case with mitochondrially targeted
XhoI (Xu et al., 2008).
A method with the potential to create any mtDNA mutation on demand
in Drosophila involves clustered regularly interspaced short palindromic
repeats (CRISPR)/Cas9 technology (Sander & Joung, 2014). Recent work
indicated this method can cleave mtDNA at the CoI locus in HEK cell mitochondria using a mitochondria-targeted Cas9 protein and introducing guide
RNAs specific for mtDNA (Jo et al., 2015). While the authors show CoI is
cut, it is not clear how the guide RNAs get into the mitochondria to mark
the CoI locus, though various RNAs are known to be imported into
eukaryotic mitochondria (Wang, Shimada, Koehler, & Teitell, 2012).
CRISPR/Cas9 works very effectively in Drosophila on nuclear genes, and
this technology appears to be more effective than gene targeting by homologous recombination in flies (Rong & Golic, 2000; Rong et al., 2002). In
the nucleus, this genome editing involves homology-directed repair that
uses an exogenously supplied oligo DNA encoding the desired change as
a template for repair. Thus, for this technology to work on mtDNA for
directed mutagenesis, there must be the appropriate repair mechanisms.
Homologous recombination between mtDNA molecules has been clearly
demonstrated for the first time in Drosophila, and the proteins required for
double-strand break repair are present in mitochondria (Duxin et al.,
2009; Ma & O’Farrell, 2015; Sage, Gildemeister, & Knight, 2010; Tann
et al., 2011; Thyagarajan, Padua, & Campbell, 1996). Thus, it may be possible to use CRISPR/Cas9 to induce specific nucleotide changes in mtDNA
to mimic human disease-causing mutations.
Point mutations in mtDNA lead to decreases in the proteins comprising the ETC complexes. While this likely occurs through a variety of
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mechanisms (e.g., too few tRNAs, unstable mRNAs, nonfunctional proteins), targeted knockdown of individual mt:mRNAs would be useful in
order to understand and characterize the resulting developmental and tissuespecific effects. Nucleus-encoded noncoding RNAs are imported into
mitochondria in all species (Sieber, Duchene, & Marechal-Drouard,
2011). Wang et al. successfully targeted wild-type mt:tRNAs to mitochondria using a 20-ribonucleotide stem–loop sequence from H1 RNA, the
RNA component of RNase P (Wang, Shimada, Zhang, et al., 2012). They
demonstrated this method could correct deficits in mt:tRNAs in cultured
cells containing mtDNA mutations. Using a variation on this theme in
Drosophila, Towheed et al. combined a similar approach with the idea of
RNA silencing (Towheed, Markantone, Crain, Celotto, & Palladino,
2014). The 5S rRNA was originally thought to be a component of only
cytoplasmic ribosomes; however, it is also imported into mitochondria
where its function is not entirely clear (Magalhaes, Andreu, & Schon,
1998; Yoshionari et al., 1994). Towheed et al. identified the Drosophila
ortholog of mitochondrial 5S rRNA and used the stem–loop leader
sequence to target antisense RNA to mitochondria (Towheed et al.,
2014). This technique resulted in translational inhibition of mt:ATP6 and
a 40–50% reduction in protein levels, which phenocopied ATP61 mutant
flies. Called mitochondrial-targeted RNA expression system (mtTRES),
the authors used the GAL4/UAS system to conditionally express the mt:
ATP6 antisense mRNA, thus giving them spatial and temporal control.
The final method to create mutated mtDNA that has not been exploited
in Drosophila, but has much potential, is creating a so-called mutator fly using
a proof-reading-deficient mitochondrial polymerase gamma (PolG). PolG,
the catalytic subunit of mtDNA polymerase, is a highly processive enzyme
that contains three exonuclease domains responsible for excising and
repairing mismatched nucleotides during replication (Kaguni & Olson,
1989; Wernette, Conway, & Kaguni, 1988). First described in yeast, PolG
mutations were created by mutating conserved residues in the exonuclease
domains, which led to an increase in mtDNA mutations as assayed by
increased erythromycin resistance (Foury & Vanderstraeten, 1992). Erythromycin, an antibiotic that targets bacterial ribosomes, affects mitochondrial
ribosomes due to the conserved mode of action between mitochondrial and
bacterial ribosomes. mtDNA mutator mice have been successfully generated
that lead to an increase in mtDNA mutations (Trifunovic et al., 2004). The
Drosophila ortholog of PolG is called Tamas (Iyengar, Roote, & Campos,
1999). Mutations in tamas are lethal, and mutations in human PolG are
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known to cause mitochondrial disease (Wong et al., 2008). One problem
with creating a mutator fly is that ectopically overexpressing tamas from a
transgene leads to a decrease in mtDNA and lethality (Lefai et al., 2000).
Using CRISPR/Cas9 would get around this problem by altering tamas at
the endogenous locus, and thus the same exonuclease mutations used in
yeast and mouse could be introduced under control of the endogenous promoter. A mutator fly would be useful for generating random mtDNA mutations and studying their effect on specific tissues, as well as inheritance. In
addition, this would potentially be a good model for examining the effect
of increased mtDNA mutation load on aging.

7. MITOCHONDRIAL INHERITANCE AND QUALITY
CONTROL CHECKPOINTS
MtDNA has a higher mutation rate than nuclear DNA. In Drosophila,
for example, it is 10 higher than the nucleus (Haag-Liautard et al., 2008;
Vermulst et al., 2007). Coupled with seemingly more rudimentary DNA
repair mechanisms, an outstanding question is how oocytes generally maintain high levels of highly functional mitochondria. During inheritance,
mitochondria can undergo a rapid change in genotype, giving rise to the
hypothesis that there is a genetic bottleneck. Evidence supports that this bottleneck may take place during oogenesis; however, where and how this happens is not fully understood (Wallace & Chalkia, 2013). Studies in bovine
indicated that a change in mtDNA genotype can be rapid, and data from
mouse have tried to pinpoint the developmental timing of the bottleneck
by estimating changes in mtDNA copy number at different times during
fetal oogenesis (Cao et al., 2007; Hauswirth & Laipis, 1982; Jenuth,
Peterson, Fu, & Shoubridge, 1996). This bottleneck was thought to be
due to random genetic drift; however, there is increasing evidence that it
may serve as a purifying mechanism to ensure only the most fit mitochondria
populate the oocyte (Fan et al., 2008; Freyer et al., 2012; Stewart et al.,
2008).
Women with disease-causing point mutations in mtDNA have a high
probability of having children affected by the disease (Taylor & Turnbull,
2005). They may not manifest any disease symptoms until later in life, or
at all, and thus may already have children. Prognoses in these cases are hard
to make. A woman whose germline is heteroplasmic can have viable oocytes
with different levels of mutated mtDNA, thus siblings can inherit different
disease severity. There are only limited tools to determine which oocytes
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have a lower mutation load. One possible remedy recently advanced is
nuclear transfer, using the affected oocyte’s nucleus and an enucleated donor
egg containing normal mitochondria (Mitalipov & Wolf, 2014). While this
method is now legal in the United Kingdom, a better understanding of the
molecular mechanisms underlying mitochondrial inheritance is required to
provide their patients with an accurate prognosis.
Drosophila are an ideal model in which to study the mechanisms responsible for mitochondrial inheritance. Drosophila oogenesis is well characterized (Spradling, 1993). The stem cells can be unambiguously identified,
each developmental stage is present for examination, and mitochondria
can be visualized at the single-organelle level (Cox & Spradling, 2003). Drosophila oocyte formation shares a surprisingly large number of similarities
with vertebrate oogenesis (Matova & Cooley, 2001). For example, both
Drosophila and vertebrate germ cells spend part of their life as a cluster of
interconnected cells called cysts (Pepling, de Cuevas, & Spradling, 1999).
The presence of cysts allows the germ cells to share cytoplasmic components,
such as microtubules, Golgi, centrosomes, and mitochondria (Cox &
Spradling, 2003; Lei & Spradling, 2016; Pepling & Spradling, 1998).
A prominent structure in oocytes is a mitochondrial cloud or Balbiani body
(Kloc, Bilinski, & Etkin, 2004). In Drosophila, this highly conserved structure
forms when a subset of mitochondria from connected sister germ cells moves
into the oocyte using the microtubule cytoskeleton and molecular motors
(Cox & Spradling, 2003, 2006). Since only a subset of mitochondria is transported into the oocyte to populate the oocyte for the first half of oogenesis,
this raises the possibility that these mitochondria may be the most highly
functional. Microtubule motor complexes appear to be important,
suggesting that the ability of a particular organelle to bind to the motor
and be transported may be part of the mechanism; however, this has not
been directly tested.
Models of mitochondrial inheritance in Drosophila have given insight to
the potential mechanisms underlying mitochondrial inheritance during
oogenesis. The original studies examining the mitochondrial bottleneck
in mouse and Drosophila took advantage of natural size differences and neutral polymorphisms between mtDNAs and did not look at competition
between deleterious mutations and wild-type mtDNA (Jenuth et al.,
1996; Kann, Rosenblum, & Rand, 1998; Solignac, Genermont,
Monnerot, & Mounolou, 1984; Solignac, Genermont, Monnerot, &
Mounolou, 1987). Recent work has used cytoplasmic injection to create
heteroplasmic flies containing wild-type and mutated mtDNAs, followed
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by monitoring of mitochondrial purification over time (Hill, Chen, & Xu,
2014; Ma, Xu, & O’Farrell, 2014). The authors of these studies have
exploited Drosophila to pinpoint the stages when mtDNA purification is taking place during oogenesis.
By carefully analyzing the percent heteroplasmy in flies over multiple
generations, Ma et al. were able to demonstrate that there is a mtDNA purifying mechanism that takes place during oogenesis (Ma et al., 2014). They
created heteroplasmic flies containing either two mutant mtDNAs (mt:CoI
and mt:ND2) or wild type and mutant. This recreated a more physiological
situation, where most mtDNA is wild type, and a small proportion contains a
deleterious lesion in the mtDNA. In agreement with previous work, deleterious mtDNA mutations paired heteroplasmically with wild-type mtDNA
were lost, giving clear-cut evidence that there is a purifying mechanism for
mutated mtDNA. When two mtDNAs for lesions in two different genes
were combined, they complemented each other and were maintained,
resulting in viable flies. This observation is satisfying, since each cell contains
many mtDNA molecules that should be able to complement function; however, this had not been demonstrated. As with mouse, the change in heteroplasmy took place quickly between mothers and their eggs, supporting that
mtDNA genotype shifts happen during oogenesis. As one of the mutations
was temperature sensitive, the authors were able to perform temperature
shift experiments to test when during oogenesis any selection may be occurring. By doing this, they found that the selection occurs after germ cell
mitotic expansion, and thus a large proportion of the selection occurs in
the later germarium stages or later during oogenesis. This coincides with
when the motor-driven Balbiani body formation occurs.
What mechanism could cause this mutant mtDNA selection during
oogenesis? One possibility is that wild-type mtDNAs have a replicative
advantage over mutated mtDNAs. Hill et al. developed a method using
5-ethynyl-20 -deoxyuridine (EdU), a thymidine analog, to examine mtDNA
replication in dissected ovaries (Hill et al., 2014). This was the first time that
mtDNA replication had been visualized during oogenesis. In wild-type flies,
they found mtDNA replication was particularly high very early in germ cell
development. This occurs right after the germ cells have completed their
mitoses and have started their meiotic program at stage 2b. In addition,
the mtDNA replication was dependent on mitochondrial function and
membrane potential as germ cells containing the temperature sensitive,
deleterious point mutation mt:CoIT300I had greatly reduced replication.
The timing of increased mtDNA replication occurred around the same
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developmental time as Ma et al. (2014) postulated selection occurs. These
two elegant studies together demonstrate the advantages of using Drosophila
to study mtDNA inheritance: the combination of genetic manipulation
(through injection to create heteroplasmic flies), the short generation time
which allows mtDNA genotypes to be followed over many generations,
immunofluorescence, and the ability to generate large sample sizes.

8. CONCLUDING REMARKS: LOSS OF MITOCHONDRIAL
FUNCTION BROADLY IMPACTS HUMAN DISEASE
Mitochondrial disease is usually defined by loss of OXPHOS. Human
mitochondrial disease is thought to affect as many as 1 in 5000 people, and
there are no cures and few effective treatments (Schaefer, Taylor,
Turnbull, & Chinnery, 2004). Because Drosophila mtDNA is so similar to
human mtDNA, there is much potential to study the cell and developmental
consequences of loss of nucleus-encoded mitochondrial proteins, and also
mutations in mtDNA. Recent manipulation of deleterious mutant mtDNA
has allowed Drosophila researchers to start to uncover the molecular mechanisms governing mtDNA inheritance and selection. Of course, mitochondria are responsible for generating many other important metabolites and are
also pivotal in cell biological processes such as apoptosis and signaling. Due
to a high demand for energy, muscle and neurons are cell types particularly
sensitive to alterations in mitochondrial output. Decreases in mitochondrial
function can lead to cardiomyopathy and heart problems, Parkinson’s disease
(reviewed in this issue), as well as other neurodegenerative diseases. Studying
mitochondria in Drosophila will continue to inform and enlighten
researchers about human mitochondrial diseases.
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